Please login to the form below
ellaOne
This page shows the latest ellaOne news and features for those working in and with pharma, biotech and healthcare.
HRA Pharma takes to social media to support its ellaOne brand
HRA Pharma has launched its emergency contraceptive brand on social media, setting up new UK-focused channels on for ellaOne on Facebook and Twitter. ... Launching ellaOne on social media is more than simply raising awareness of a suitable EC method, in
Latest news
-
HRA launches 'fairytale' digital ad campaign for ellaOne brand
HRA Pharma has launched a digital advertising campaign in the UK for its non-prescription emergency contraceptive brand ellaOne. ... It aims to show accidents can happen to anyone and increase awareness of the options - including ellaOne - available to
-
Golin Health wins HRA Pharma and Atlantis Healthcare accounts
For HRA Pharma Golin will be working to raise awareness of the French company's emergency contraceptive pill ellaOne (ulipristal acetate) in the UK, targeting both pharmacists and women of childbearing ... age. EllaOne was granted EU-wide approval by the
-
Five companies breach ABPI code
ellaOne (ulipristal acetate).
-
Watson launches ella in US
Ulipristal acetate has been available in Europe since October 2009, where it is marketed by HRA Pharma as EllaOne.
-
Clouded vision
Speciality European Pharma) . Overactive bladder . UK. Ulipristal acetate. ellaOne (HRA Pharma).
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
The pill branding
the binding landmark decision of switching the ellaOne (ulipristal acetate) pill to an OTC drug. ... Finally, ellaOne will be available over the counter in all European countries except for Hungary.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
